0001203311-22-000013.txt : 20220209
0001203311-22-000013.hdr.sgml : 20220209
20220209185805
ACCESSION NUMBER: 0001203311-22-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220207
FILED AS OF DATE: 20220209
DATE AS OF CHANGE: 20220209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRYSKA DAVID W
CENTRAL INDEX KEY: 0001202335
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-32405
FILM NUMBER: 22608902
MAIL ADDRESS:
STREET 1: 749 N MARY AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seagen Inc.
CENTRAL INDEX KEY: 0001060736
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 911874389
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4255274000
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: SEATTLE GENETICS INC /WA
DATE OF NAME CHANGE: 20001116
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2022-02-07
0
0001060736
Seagen Inc.
SGEN
0001202335
GRYSKA DAVID W
21823 30TH DRIVE SE
BOTHELL
WA
98021
1
0
0
0
Common Stock
2022-02-07
4
M
0
1100
20.06
A
47350
D
Common Stock
2022-02-07
4
S
0
1100
137.45
D
46250
D
Common Stock
2022-02-07
4
M
0
1029
20.06
A
47279
D
Common Stock
2022-02-07
4
S
0
1029
138.66
D
46250
D
Common Stock
2022-02-07
4
M
0
2371
20.06
A
48621
D
Common Stock
2022-02-07
4
S
0
2371
139.42
D
46250
D
Non-Qualified Stock Option (right to buy)
20.06
2022-02-07
4
M
0
1100
0.0
D
2022-05-17
Common Stock
1100
7400
D
Non-Qualified Stock Option (right to buy)
20.06
2022-02-07
4
M
0
1029
0.0
D
2022-05-17
Common Stock
1029
6371
D
Non-Qualified Stock Option (right to buy)
20.06
2022-02-07
4
M
0
2371
0.0
D
2022-05-17
Common Stock
2371
4000
D
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Reflects sales of common stock executed in multiple transactions at prices ranging from $137.03 to $137.98. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $138.03 to $139.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $139.20 to $139.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Options were fully vested on 5/17/13.
By: /s/ Jennifer Prosba For: David W. Gryska
2022-02-09